Authors:
MCLEAN A
BROWNE S
ZHANG YX
SLAUGHTER E
HALSTENSON C
COUCH R
Citation: A. Mclean et al., BIOAVAILABILITY OF A TWICE-DAILY CONTROLLED-RELEASE CARBAMAZEPINE - INFLUENCE OF FOOD, DOSE EQUIVALENCY, AND DOSE PROPORTIONALITY, Annals of neurology, 44(3), 1998, pp. 224-224
Authors:
DIMMITT DC
SHAH AK
ARUMUGHAM T
CRAMER IB
HALSTENSON C
HORTON M
WEIR SJ
Citation: Dc. Dimmitt et al., PHARMACOKINETICS OF ORAL AND INTRAVENOUS DOLASETRON MESYLATE IN PATIENTS WITH RENAL IMPAIRMENT, Journal of clinical pharmacology, 38(9), 1998, pp. 798-806
Authors:
KHAN MA
HARDEY G
STPETER JV
PHELEY A
HALSTENSON C
NICOL S
Citation: Ma. Khan et al., IMPROVEMENT OF CARDIOVASCULAR-DISEASE RISK-FACTORS IN OBESE-DIABETIC AND NONDIABETIC PATIENTS AFTER 12 MONTHS OF PHENTERMINE FENFLURAMINE (PHEN/FEN) THERAPY/, The American journal of clinical nutrition, 66(1), 1997, pp. 111-111
Authors:
SHAH J
BULLINGHAM R
RICE P
TSINA I
SWAN S
HALSTENSON C
Citation: J. Shah et al., PHARMACOKINETICS OF ORAL MYCOPHENOLATE MOFETIL (MMF) AND METABOLITES IN RENALLY IMPAIRED PATIENTS, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 149-149
Authors:
SWAN SK
RADWANSKI E
CUTLER D
AFFRIME M
SCOTT M
HALSTENSON C
Citation: Sk. Swan et al., PHARMACOKINETICS OF FLUTAMIDE (F) IN PATIENTS WITH RENAL-INSUFFICIENCY (RI), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 207-207